Patents Assigned to THE RNA MEDICINES COMPANY, INC.
  • Publication number: 20200048686
    Abstract: The present disclosure relates to development and performance of screening methods capable of efficiently identifying candidate lead compounds that bind regulatory RNA oligonucleotides in a sequence-specific manner and exert a biological effect upon such regulatory molecules. Candidate lead compounds possessing RNA binding sequence specificity and targeted biological activity are described, as are approaches for merging structural, NMR-derived data with biological reporter assay results. Compound validation approaches capable of identifying the site(s) of action of such compounds within targeted RNA oligonucleotides are also provided.
    Type: Application
    Filed: April 26, 2018
    Publication date: February 13, 2020
    Applicant: THE RNA MEDICINES COMPANY, INC.
    Inventors: Dalia Cohen, Michelle Markus, Jun Jiang, Michel Guiraldelli, Justin Boyd, Branko Radetich, Nanguneri Nirmala, Johan Pontin